Please assess the completion status of the following clinical trial:

Trial Title: Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients may be eligible for this study if they:~* Are between the ages of 0 and 20 years (prior to their 21st birthday)~* Are receiving their first living related (e.g.,kidney from a relative or unrelated donor) or cadaver donor transplant~* Are willing to practice an acceptable method of birth control during the study, if women able to have children~Exclusion Criteria:~Patients will not be eligible for this study if they:~* Have received multiple organs~* Have received 2 or more transplants~* Have an active infection (including tuberculosis), or cancer~* Have used an experimental agent within 4 weeks of transplantation

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Corticosteroid (steroid) withdrawal (Type: EXPERIMENTAL): All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
- Control Treatment (Type: ACTIVE_COMPARATOR): All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).